The 131st Annual Meeting (November 15-19, 2003) of APHA |
Leslie Cooper, PhD, ERB/DESPR/NIDA/NIH, 6001 Executive Blvd, Suite 5167, Bethesda, MD 20892, 301-443-6637, lc58q@nih.gov and Dionne Jones, PhD, Center on AIDS and Other Medical Consequences of Drug Abuse (CAMCODA), National Institute on Drug Abuse, 6001 Executive Boulevard, Room 5198, Bethesda, MD 20892.
The primary goal of NIDA's SAI is to stimulate bi-national collaborative drug abuse research among the United States and Southern African countries in the areas of: Basic Research, Epidemiology/Early Interventions, Clinical Neurobiology, Prevention, Treatment, or Health Services Research aimed at reducing drug abuse/addiction and its associated adverse behavioral, social, and health consequences (e.g., violence, infectious diseases-HCV, HIV/AIDS, and pulmonary diseases). All studies/activities proposed under this Initiative address issues of health disparities where appropriate, and must be culturally appropriate, feasible, and acceptable for implementation in Southern Africa and the United States. The overall goal of this collaborative effort is to inform and advance substance abuse research both in the United States and Southern Africa. This panel will share present information on the collaborations established between researchers in the United States and in Southern Africa as they work towards building the infrastructure to advance the science of drug abuse, HIV and other adverse health behaviors and consequences in both regions. Parallels between both countries and differencies will be identified with the potential for early intervention and prevention strategies.
Learning Objectives:
Keywords: International,
Related Web page: www.nida.nih.gov
Presenting author's disclosure statement:
Organization/institution whose products or services will be discussed: Research Supported by the National Institutes of Health
I do not have any significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.